|
1
|
Jabbour E and Kantarjian H: Chronic
myeloid leukemia: 2020 update on diagnosis, therapy and monitoring.
Am J Hematol. 95:691–709. 2020.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Rinaldi I and Winston K: Chronic myeloid
leukemia, from pathophysiology to treatment-free remission: A
narrative literature review. J Blood Med. 14:261–277.
2023.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Osman AEG and Deininger MW: Chronic
myeloid leukemia: Modern therapies, current challenges and future
directions. Blood Rev. 49(100825)2021.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Arber DA, Orazi A, Hasserjian RP, Borowitz
MJ, Calvo KR, Kvasnicka HM, Wang SA, Bagg A, Barbui T, Branford S,
et al: International consensus classification of myeloid neoplasms
and acute leukemias: Integrating morphologic, clinical and genomic
data. Blood. 140:1200–1228. 2022.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Thakral B, Saluja K, Malhotra P, Sharma
RR, Marwaha N and Varma S: Therapeutic plateletpheresis in a case
of symptomatic thrombocytosis in chronic myeloid leukemia. Ther
Apher Dial. 8:497–499. 2004.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Ebrahem R, Ahmed B, Kadhem S and Truong Q:
Chronic myeloid leukemia: A case of extreme thrombocytosis causing
syncope and myocardial infarction. Cureus. 8(e476)2016.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Turakhia SK, Murugesan G, Cotta CV and
Theil KS: Thrombocytosis and STAT5 activation in chronic
myelogenous leukaemia are not associated with JAK2 V617F or
calreticulin mutations. J Clin Pathol. 69:713–719. 2016.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Chiatamone Ranieri S, Arleo MA, Trasarti
S, Bizzoni L, Carmosino I, De Luca ML, Mohamed S, Mariggiò E,
Scalzulli E, Rosati S, et al: Clinical and prognostic features of
essential thrombocythemia: Comparison of 2001 WHO Versus 2008/2016
WHO criteria in a large single-center cohort. Clin Lymphoma Myeloma
Leuk. 21:e328–e333. 2021.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Haznedaroglu IC: The therapeutic goals of
essential thrombocythemia under the clouds of over-treatment and
under-treatment. Expert Opin Pharmacother. 14:1431–1436.
2013.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Verma SP, Subbiah A, Jacob SE and Basu D:
Chronic myeloid leukaemia with extreme thrombocytosis. BMJ Case
Rep. 2015(bcr2014204564)2015.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Talpaz M: Interferon-alfa-based treatment
of chronic myeloid leukemia and implications of signal transduction
inhibition. Semin Hematol. 38 (Suppl 8):S22–S27. 2001.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Palandri F, Castagnetti F, Iacobucci I,
Martinelli G, Amabile M, Gugliotta G, Poerio A, Testoni N, Breccia
M, Bocchia M, et al: The response to imatinib and interferon-alpha
is more rapid than the response to imatinib alone: A retrospective
analysis of 495 Philadelphia-positive chronic myeloid leukemia
patients in early chronic phase. Haematologica. 95:1415–1419.
2010.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Liu Z, Fan H, Li Y and Liu C: Analysis of
clinical characteristics and efficacy of chronic myeloid leukemia
onset with extreme thrombocytosis in the era of tyrosine kinase
inhibitors. Onco Targets Ther. 10:3515–3520. 2017.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Tefferi A and Barbui T: Polycythemia vera
and essential thrombocythemia: 2021 update on diagnosis,
risk-stratification and management. Am J Hematol. 95:1599–1613.
2020.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Jang MA and Choi CW: Recent insights
regarding the molecular basis of myeloproliferative neoplasms.
Korean J Intern Med. 35:1–11. 2020.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Byun YJ, Park BB, Lee ES, Choi KS and Lee
DS: A case of chronic myeloid leukemia with features of essential
thrombocythemia in peripheral blood and bone marrow. Blood Res.
49:127–129. 2014.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Hiruma K, Saitoh H, Someya K and Kashimura
M: Hematologic abnormalities in a patient with chronic myelogenous
leukemia with advanced myelofibrosis were improved by G-CSF. Rinsho
Ketsueki. 35:135–141. 1994.PubMed/NCBI(In Japanese).
|
|
18
|
Shah NP: Front-line treatment options for
chronic-phase chronic myeloid leukemia. J Clin Oncol. 36:220–224.
2018.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Granatowicz A, Piatek CI, Moschiano E,
El-Hemaidi I, Armitage JD and Akhtari M: An overview and update of
chronic myeloid leukemia for primary care physicians. Korean J Fam
Med. 36:197–202. 2015.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Rajabto W and Angkasa YK: Asymptomatic
chronic-phase chronic myeloid leukemia BCR-ABL. (+) without
splenomegaly: A case report. Niger J Clin Pract. 25:373–375.
2022.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Galvez C and Stein BL: Thrombocytosis and
thrombosis: Is there really a correlation? Curr Hematol Malig Rep.
15:261–267. 2020.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Zheng Y, Wen J and Li J: Pediatric chronic
myeloid leukemia presenting with extreme thrombocytosis and acute
upper gastrointestinal hemorrhage: A case report. J Pediatr Hematol
Oncol. 43:e1049–e1051. 2021.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Turroni S, Tolomeo M, Mamone G, Picariello
G, Giacomini E, Brigidi P, Roberti M, Grimaudo S, Pipitone RM, Di
Cristina A and Recanatini M: A natural-like synthetic small
molecule impairs bcr-abl signaling cascades and induces
megakaryocyte differentiation in erythroleukemia cells. PLoS One.
8(e57650)2013.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Thiele J, Kvasnicka HM, Varus E, Ollig E,
Schmitt-Graeff A, Staib P and Griesshammer M: Megakaryocyte
features and bcr/abl translocation in chronic myeloid leukemia
following imatinib mesylate (STI571) therapy-a fluorescence in-situ
hybridization study. Leuk Lymphoma. 45:1627–1631. 2004.PubMed/NCBI View Article : Google Scholar
|
|
25
|
ten Bosch GJ, Kessler JH, Blom J, Joosten
AM, Gambacorti-Passerini C, Melief CJ and Leeksma OC: BCR-ABL
oncoprotein is expressed by platelets from CML patients and
associated with a special pattern of CrkL phosphorylation. Br J
Haematol. 103:1109–1115. 1998.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Bennour A, Ouahchi I, Achour B, Zaier M,
Youssef YB, Khelif A, Saad A and Sennan H: Analysis of the
clinico-hematological relevance of the breakpoint location within
M-BCR in chronic myeloid leukemia. Med Oncol.
30(348)2013.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Arana-Trejo RM, Ruíz Sánchez R,
Ignacio-Ibarra G, Báez de la Fuente E, Garces O, Gómez Morales E,
Castro Granados M, Ovilla Martínez R, Rubio-Borja ME, Solís Anaya
L, et al: BCR/ABL p210, p190 and p230 fusion genes in 250 Mexican
patients with chronic myeloid leukaemia (CML). Clin Lab Haematol.
24:145–150. 2002.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Polampalli S, Choughule A, Negi N, Shinde
S, Baisane C, Amre P, Subramanian PG, Gujral S, Prabhash K and
Parikh P: Analysis and comparison of clinicohematological
parameters and molecular and cytogenetic response of two Bcr/Abl
fusion transcripts. Genet Mol Res. 7:1138–1149. 2008.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Al-Achkar W, Moassass F, Youssef N and
Wafa A: Correlation of p210 BCR-ABL transcript variants with
clinical, parameters and disease outcome in 45 chronic myeloid
leukemia patients. J BUON. 21:444–449. 2016.PubMed/NCBI
|
|
30
|
Pane F, Mostarda I, Selleri C, Salzano R,
Raiola AM, Luciano L, Saglio G, Rotoli B and Salvatore F: BCR/ABL
mRNA and the P210(BCR/ABL) protein are downmodulated by
interferon-alpha in chronic myeloid leukemia patients. Blood.
94:2200–2207. 1999.PubMed/NCBI
|
|
31
|
Junmei Z, Fengkuan Y, Yongping S, Baijun
F, Yuzhang L, Lina L and Qinglan Z: Coexistence of P190 and P210
BCR/ABL transcripts in chronic myeloid leukemia blast crisis
resistant to imatinib. Springerplus. 4(170)2015.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Zhang X, Sun H, Su Y and Yi H: Long-term
molecular remission after treatment with imatinib in a chronic
myeloid leukemia patient with extreme thrombocytosis harboring rare
e14a3 (b3a3) BCR::ABL1 transcript: A case report. Curr Oncol.
29:8171–8179. 2022.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Puil L, Liu JX, Gish G, Mbamalu G, Bowtell
D, Pelicci PG, Arlinghaus R and Pawson T: Bcr-Abl oncoproteins bind
directly to activators of the Ras signalling pathway. EMBO J.
13:764–773. 1994.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Liu RY, Fan C, Garcia R, Jove R and
Zuckerman KS: Constitutive activation of the JAK2/STAT5 signal
transduction pathway correlates with growth factor independence of
megakaryocytic leukemic cell lines. Blood. 93:2369–2379.
1999.PubMed/NCBI
|
|
35
|
Verma D, Kantarjian HM, Jones D, Luthra R,
Borthakur G, Verstovsek S, Rios MB and Cortes J: Chronic myeloid
leukemia (CML) with P190 BCR-ABL: Analysis of characteristics,
outcomes and prognostic significance. Blood. 114:2232–2235.
2009.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Melo JV: BCR-ABL gene variants. Baillieres
Clin Haematol. 10:203–222. 1997.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Balatzenko G, Guenova M, Stoimenov A,
Jotov G and Toshkov S: Philadelphia chromosome-positive chronic
myeloid leukemia with p190(BCR-ABL) rearrangement, overexpression
of the EVI1 gene and extreme thrombocytosis: A case report. Cancer
Genet Cytogenet. 181:75–77. 2008.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Adnan-Awad S, Kim D, Hohtari H, Javarappa
KK, Brandstoetter T, Mayer I, Potdar S, Heckman CA, Kytölä S,
Porkka K, et al: Characterization of p190-Bcr-Abl chronic myeloid
leukemia reveals specific signaling pathways and therapeutic
targets. Leukemia. 35:1964–1975. 2021.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Gleissner B, Gökbuget N, Bartram CR,
Janssen B, Rieder H, Janssen JW, Fonatsch C, Heyll A, Voliotis D,
Beck J, et al: Leading prognostic relevance of the BCR-ABL
translocation in adult acute B-lineage lymphoblastic leukemia: A
prospective study of the German Multicenter Trial Group and
confirmed polymerase chain reaction analysis. Blood. 99:1536–1543.
2002.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Qiu LL, Lu YJ, Jing Y, Yu L, Liu DH and
Wang LL: Comparison of clinical outcomes between P190 and P210
trans-cripts in adult Ph chromosome positive acute lymphoblastic
leukemia in the new Era of TKI. Zhongguo Shi Yan Xue Ye Xue Za Zhi.
24:369–374. 2016.PubMed/NCBI View Article : Google Scholar : (In Chinese).
|
|
41
|
Vasconcelos AP, Azevedo IF, Melo FCBC,
Neves WB, Azevedo ACAC and Melo RAM: BCR-ABL1 transcript types
showed distinct laboratory characteristics in patients with chronic
myeloid leukemia. Genet Mol Res. 16:2017.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Guglielmelli P and Calabresi L: The MPL
mutation. Int Rev Cell Mol Biol. 365:163–178. 2021.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Stockklausner C, Duffert CM, Cario H,
Knöfler R, Streif W and Kulozik AE: THROMKID-Plus Studiengruppe der
Gesellschaft für Thrombose-und Hämostaseforschung (GTH) and of
Gesellschaft für Pädiatrische Onkologie und Hämatologie (GPOH).
Thrombocytosis in children and adolescents-classification,
diagnostic approach and clinical management. Ann Hematol.
100:1647–1665. 2021.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Rottenstreich A and Bussel JB: Treatment
of immune thrombocytopenia during pregnancy with thrombopoietin
receptor agonists. Br J Haematol. 203:872–885. 2023.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Rubenstein AI, Pierson SK, Shyamsundar S,
Bustamante MS, Gonzalez MV, Milller ID, Brandstadter JD, Mumau MD
and Fajgenbaum DC: Immune-mediated thrombocytopenia and
IL-6-mediated thrombocytosis observed inidiopathic multicentric
Castleman disease. Br J Haematol. 204:921–930. 2024.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Wolfe HR and Rein LAM: The evolving
landscape of frontline therapy in chronic phase chronic myeloid
leukemia (CML). Curr Hematol Malig Rep. 16:448–454. 2021.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Flynn JP and Gerriets V: Imatinib. In:
StatPearls. StatPearls Publishing, Treasure Island, FL, 2025.
|
|
48
|
Gao L, Ren MQ, Tian ZG, Peng ZY, Shi G and
Yuan Z: Management of chronic myeloid leukemia presenting with
isolated thrombocytosis and complex Philadelphia chromosome: A case
report. Medicine (Baltimore). 100(e27134)2021.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Repsold L, Pool R, Karodia M, Tintinger G,
Becker P and Joubert AM: Apoptotic profiling of chronic myeloid
leukaemia patients' platelets ex vivo before and after treatment
with Imatinib. Cell Biochem Funct. 39:562–570. 2021.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Sener Y, Okay M, Aydin S, Buyukasik Y,
Akbiyik F and Dikmen ZG: TKI-related platelet dysfunction does not
correlate with bleeding in patients with chronic phase-chronic
myeloid leukemia with complete hematological response. Clin Appl
Thromb Hemost. 25(1076029619858409)2019.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Shu LL, Jiang QL, Meng FY and Yang M:
Molecular mechanism of imatinib-induced thrombocytopenia in
treatment of patients with CML. Zhongguo Shi Yan Xue Ye Xue Za Zhi.
19:1314–1318. 2011.PubMed/NCBI(In Chinese).
|
|
52
|
Repsold L, Pool R, Karodia M, Tintinger G
and Joubert AM: Ex vivo platelet morphology assessment of chronic
myeloid leukemia patients before and after Imatinib treatment.
Microsc Res Tech. 85:2222–2233. 2022.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Akram AM, Iqbal Z, Akhtar T, Khalida AM,
Sabar MF, Qazi MH, Azize Z, Sajid N, Aleem A, Rasoolh M, et al:
Presence of novel compound BCR-ABL mutations in late chronic and
advanced phase imatinib sensitive CML patients indicates their
possible role in CML progression. Cancer Biol Ther. 18:214–221.
2017.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Al-Ali HK, Heinrich MC, Lange T, Krahl R,
Mueller M, Müller C, Niederwieser D, Druker BJ and Deininger MW:
High incidence of BCR-ABL kinase domain mutations and absence of
mutations of the PDGFR and KIT activation loops in CML patients
with secondary resistance to imatinib. Hematol J. 5:55–60.
2004.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Tanaka R and Kimura S: Abl tyrosine kinase
inhibitors for overriding Bcr-Abl/T315I: From the second to third
generation. Expert Rev Anticancer Ther. 8:1387–1398.
2008.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Dhillon S: Olverembatinib: First approval.
Drugs. 82:469–475. 2022.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Binzaid AA, Baqal OJ, Soheib M, Nahedh MA,
Samarkandi HH and Aljurf M: Cardiovascular toxicity associated with
tyrosine kinase inhibitor therapy in chronic myeloid leukemia. Gulf
J Oncolog. 1:79–84. 2021.PubMed/NCBI
|
|
58
|
Caocci G, Mulas O, Annunziata M, Luciano
L, Abruzzese E, Bonifacio M, Orlandi EM, Albano F, Galimberti S,
Iurlo A, et al: Long-term mortality rate for cardiovascular disease
in 656 chronic myeloid leukaemia patients treated with second- and
third-generation tyrosine kinase inhibitors. Int J Cardiol.
301:163–166. 2020.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Robak T: Use of interferon in the
treatment of chronic myeloproliferative disorders. Acta Haematol
Pol. 23 (2 Suppl 1):S30–S37. 1992.PubMed/NCBI(In Polish).
|
|
60
|
Talpaz M, Mercer J and Hehlmann R: The
interferon-alpha revival in CML. Ann Hematol. 94 (Suppl
2):S195–S207. 2015.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Kujawski LA and Talpaz M: The role of
interferon-alpha in the treatment of chronic myeloid leukemia.
Cytokine Growth Factor Rev. 18:459–471. 2007.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Seewann HL: Interferon therapy in
essential thrombocythemia. Wien Med Wochenschr. 143:420–424.
1993.PubMed/NCBI(In German).
|
|
63
|
Koike G, Otsuka T, Shibuya T and Niho Y:
Thrombocytosis in chronic myelogenous leukemia (CML) controlled by
interferon alpha (IFN-alpha). Rinsho Ketsueki. 30:400–403.
1989.PubMed/NCBI(In Japanese).
|
|
64
|
Thiele J, Zirbes T, Kvasnicka HM, Niederle
N, Dammasch J, Schmidt M, Windecker R, Leder LD, Diehl V and
Fischer R: Interferon therapy, but not busulfan restores
normal-sized megakaryopoiesis in CML-a comparative histo- and
immunomorphometric study. Anal Cell Pathol. 11:31–42.
1996.PubMed/NCBI
|
|
65
|
Kong J, Qin YZ, Zhao XS, Hou Y, Liu KY,
Huang XJ and Jiang H: Profiles of NK cell subsets are associated
with successful tyrosine kinase inhibitor discontinuation in
chronic myeloid leukemia and changes following interferon
treatment. Ann Hematol. 100:2557–2566. 2021.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Rüdiger H, andreas H and Michele B:
European LeukemiaNet. Chronic myeloid leukaemia. Lancet.
370:342–350. 2007.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Gabriele L, Borghi P, Rozera C, Sestili
Pandreotti M, Guarini A, Montefusco E, Foà R and Belardelli F:
IFN-alpha promotes the rapid differentiation of monocytes from
patients with chronic myeloid leukemia into activated dendritic
cells tuned to undergo full maturation after LPS treatment. Blood.
103:980–987. 2004.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Simonsson B, Gedde-Dahl T, Markevärn B,
Remes K, Stentoft J, Almqvist A, Björeman M, Flogegård M,
Koskenvesa P, Lindblom A, et al: Combination of pegylated IFN-α2b
with imatinib increases molecular response rates in patients with
low- or intermediate-risk chronic myeloid leukemia. Blood.
118:3228–3235. 2011.PubMed/NCBI View Article : Google Scholar
|
|
69
|
McGlave P, Mamus S, Vilen B and Dewald G:
Effect of recombinant gamma interferon on chronic myelogenous
leukemia bone marrow progenitors. Exp Hematol. 15:331–335.
1987.PubMed/NCBI
|
|
70
|
Foon KA, Sherwin SA, Abrams PG, Stevenson
HC, Holmes P, Maluish AE, Oldham RK and Herberman RB: A phase I
trial of recombinant gamma interferon in patients with cancer.
Cancer Immunol Immunother. 20:193–197. 1985.PubMed/NCBI View Article : Google Scholar
|
|
71
|
Dou XL, Wang SS, Fang JL, Yu L, Ren X,
Huang XJ and Jiang Q: Hepatic adverse events associated with
tyrosine kinase inhibitors in patients with chronic myeloid
leukemia. Zhonghua Nei Ke Za Zhi. 57:649–655. 2018.PubMed/NCBI View Article : Google Scholar : (In Chinese).
|
|
72
|
O'Brien S, Kantarjian H and Talpaz M:
Practical guidelines for the management of chronic myelogenous
leukemia with interferon alpha. Leuk Lymphoma. 23:247–252.
1996.PubMed/NCBI View Article : Google Scholar
|
